|
FY2025
12 months to Dec 31, 2025
|
FY2023
12 months to Jun 30, 2024
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development (including $10,125,000 for the year ended December 31, 2025 and $2,801,435 for the six months ended December 31, 2024, from a related party) | ||||
| General and administrative | ||||
| Total operating expenses | ||||
| Loss from Operations | ||||
| Loss before income taxes | ||||
| Income tax provision | ||||
| Net loss | ||||
| Net loss applicable to common stock per share, basic (in Dollars per share) | ||||
| Total net loss applicable to common stock per share, basic (in Dollars per share) | ||||
| Net loss applicable to common stock per share, diluted (in Dollars per share) | ||||
| Total net loss applicable to common stock per share, diluted (in Dollars per share) | ||||
| Weighted average common stock outstanding, basic (in Shares) | ||||
| Total weighted average common stock outstanding, basic (in Shares) | ||||
| Weighted average common stock outstanding, diluted (in Shares) | ||||
| Total weighted average common stock outstanding, diluted (in Shares) | ||||
Loading...